The DOI matches its Crossref record; 617 of the 617 references it cites were found in a registry or an index.
Bioactive lipids, inflammation and chronic diseases
Abstract
Endogenous bioactive lipids are part of a complex network that modulates a plethora of cellular and molecular processes involved in health and disease, of which inflammation represents one of the most prominent examples. Inflammation serves as a well-conserved defence mechanism, triggered in the event of chemical, mechanical or microbial damage, that is meant to eradicate the source of damage and restore tissue function. However, excessive inflammatory signals, or impairment of pro-resolving/anti-inflammatory pathways leads to chronic inflammation, which is a hallmark of chronic pathologies. All main classes of endogenous bioactive lipids - namely eicosanoids, specialized pro-resolving lipid mediators, lysoglycerophopsholipids and endocannabinoids - have been consistently involved in the chronic inflammation that characterises pathologies such as cancer, diabetes, atherosclerosis, asthma, as well as autoimmune and neurodegenerative disorders and inflammatory bowel diseases. This review gathers the current knowledge concerning the involvement of endogenous bioactive lipids in the pathogenic processes of chronic inflammatory pathologies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 601–617 of 617
Fukuda, H., Abe, T., & Yoshihara, S. (2010) · International Archives of Allergy and Immunology · doi:10.1159/000283042 · Cited by 19
ABHD2 Inhibitor Identified by Activity-Based Protein Profiling Reduces Acrosome Reaction
Baggelaar, M. P., den Dulk, H., Florea, B. I., Fazio, D., Bernabò, N., Raspa, M., Janssen, A. P. A., Scavizzi, F., Barboni, B., Overkleeft, H. S., et al. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.9b00640 · Cited by 19
Self-citationEasley, J. T., Maruyama, C. L., Wang, C.-S., & Baker, O. J. (2016) · Physiological Reports · doi:10.14814/phy2.12990 · Cited by 18
Targeting fatty acid amide hydrolase as a therapeutic strategy for antitussive therapy
Wortley, M. A., Adcock, J. J., Dubuis, E. D., Maher, S. A., Bonvini, S. J., Delescluse, I., Kinloch, R. A., McMurray, G., Huguet, C., Papakosta, M., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.00782-2017 · Cited by 18
The EP3 Receptor: Exploring a New Target for Type 2 Diabetes Therapeutics.
Neuman, J. C., & Kimple, M. E. (2013) · PubMed · Cited by 17
de Brito, N. M., da-Costa, H. C., Simões, R. L., & Barja‐Fidalgo, C. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00540 · Cited by 17
Gastroduodenal mucosal defense mechanisms
Said, H., Kaji, I., & Kaunitz, J. D. (2015) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000211 · Cited by 16
Grossmayer, G. E., Keppeler, H., Boeltz, S., Janko, C., Rech, J., i, M. H., Lauber, K., & Munoz, L. E. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01876 · Cited by 16
Kulinski, J. M., Proia, R. L., Larson, E. M., Metcalfe, D. D., & Olivera, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051279 · Cited by 16
Seeing the future of bioactive lipid drug targets
Evans, J. F., & Hutchinson, J. H. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.394 · Cited by 15
Albi, E., Cataldi, S., Ceccarini, M. R., Conte, C., Ferri, I., Fettucciari, K., Patria, F. F., Beccari, T., & Codini, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184375 · Cited by 15
Emerging drugs to treat glaucoma: targeting prostaglandin F and E receptors
Lusthaus, J. A., & Goldberg, I. (2016) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2016.1151001 · Cited by 13
Examination of the role of sphingosine kinase 2 in a murine model of systemic lupus erythematosus
Mohammed, S., Vineetha, N. S., James, S., Aparna, J. S., Lankadasari, M. B., Allegood, J. C., Li, Q., Spiegel, S., & Harikumar, K. B. (2019) · The FASEB Journal · doi:10.1096/fj.201802535r · Cited by 12
Inhaled anandamide reduces leukotriene D4-induced airway obstruction in guinea pigs
Stengel, P. W., Cockerham, S. L., & Silbaugh, S. A. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.11.025 · Cited by 11
Inhibition of lysophosphatidic acid receptor ameliorates Sjögren's syndrome in NOD mice
Park, E., Kim, D., Lee, S. M., & Jun, H. (2017) · Oncotarget · doi:10.18632/oncotarget.15916 · Cited by 11
Abnormal anandamide metabolism in celiac disease
Battista, N., Sabatino, A. D., Tommaso, M. D., Biancheri, P., Rapino, C., Vidali, F., Papadia, C., Montana, C., Pasini, A., Lanzini, A., et al. (2011) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2011.06.017 · Cited by 10
Self-citationRole for peroxisome proliferator-activated receptor-gamma in Alzheimer's disease.
van Geel (2001) · Open Repository and Bibliography (University of Luxembourg) · doi:10.1002/1531-8249(20010201)49:2 · Cited by 7
Cited by
Soppert, J., Lehrke, M., Marx, N., Jankowski, J., & Noels, H. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.019 · Cited by 407
The effects of microglia-associated neuroinflammation on Alzheimer’s disease
Wang, C., Zong, S., Cui, X., Wang, X., Wu, S., Wang, L., Liu, Y., & Lu, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1117172 · Cited by 298
Han, X., Wu, X., Liu, F., Chen, H., & Hou, H. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117942 · Cited by 21
The lipid paradox in neuroprogressive disorders: Causes and consequences
Morris, G., Berk, M., Walder, K., O’Neil, A., Maes, M., & Puri, B. K. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.06.017 · Cited by 17
An iPSC-derived astrocyte model of fragile X syndrome exhibits dysregulated cholesterol homeostasis
Talvio, K., Wagner, V. A., Minkeviciene, R., Kirkwood, J. S., Kulinich, A. O., Umemori, J., Bhatia, A., Hur, M., Käkelä, R., Ethell, I. M., et al. (2023) · Communications Biology · doi:10.1038/s42003-023-05147-9 · Cited by 8
Metadata
- Authors
- Leuti, A., Fazio, D., Fava, M., Piccoli, A., Oddi, S., & Maccarrone, M.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2020
- Volume
- 159
- Pages
- 133-169
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W3039772549
- Cited by
- 358
- References
- 617
- FWCI
- 7.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.